SCHEMBL1241605

SCHEMBL1241605

FC(F)(F)c1ccc(NCC2CCCC2)cc1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LIPC P11150 1/20 0.46
LIPG Q9Y5X9 1/20 0.46
MEN1 O00255 1/20 0.45
LMNA P02545 1/20 0.45
HTT P42858 1/20 0.45
KMT2A Q03164 1/20 0.45
SMN1; SMN2 Q16637 1/20 0.45
RXFP1 Q9HBX9 1/20 0.44
JAK2 O60674 1/20 0.44
JAK1 P23458 1/20 0.44
CRHR1 P34998 2/20 0.43
HDAC6 Q9UBN7 2/20 0.41
MLYCD O95822 1/20 0.41
ALDH1A1 P00352 1/20 0.41
ALDH3A1 P30838 1/20 0.41
SLC6A4 P31645 1/20 0.40
SLC6A3 Q01959 1/20 0.40
MGLL Q99685 1/20 0.40
NAMPT P43490 1/20 0.40
IDH1 O75874 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13439172 0.85 LIPC (0.46) LIPCLIPGJAK2JAK1CRHR1
SCHEMBL2096323 0.85 JAK2 (0.44) LIPCLIPGMEN1LMNAHTT
SCHEMBL11935145 0.85 LIPC (0.46) LIPCLIPGJAK2JAK1CRHR1
SCHEMBL2056107 0.82 HTR2A (0.48) LIPCLIPGJAK2JAK1CRHR1
SCHEMBL12245529 0.81 CHRNB4 (0.47) LIPCLIPGMEN1LMNAHTT
SCHEMBL30288262 0.80 RXFP1 (0.61) LIPCLIPGLMNARXFP1CRHR1
SCHEMBL1241128 0.80 RXFP1 (0.61) LIPCLIPGLMNARXFP1CRHR1
SCHEMBL1240850 0.78 POLB (0.60) MEN1HTTKMT2AJAK2JAK1
SCHEMBL22414312 0.78 RAB9A (0.44) KMT2ASMN1; SMN2JAK2JAK1ALDH1A1
SCHEMBL1565671 0.78 RAB9A (0.44) KMT2ASMN1; SMN2JAK2JAK1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8586614-B2 Urea glucokinase activators NOVO NORDISK A/S (DK) 2013-11-19 US disclosed
US-20110077234-A1 Urea Glucokinase Activators NOVO NORDISK A/S (DK) 2011-03-31 US disclosed
US-7884210-B2 {2-[3-(2-Cyclohex-1-enyl-ethyl)-3-(trans-4-methyl-cyclohexyl)-ureido]-thiazol-5-ylsulfanyl}-acetic acid; for treatment of type 2 diabetes NOVO NORDISK A/S (DK) 2011-02-08 US disclosed
US-20090105482-A1 Urea Glucokinase Activators NOVO NORDISK A/S (DK) 2009-04-23 US disclosed
EP-1904467-A1 UREA GLUCOKINASE ACTIVATORS Novo Nordisk A/S (DK) 2008-04-02 EP disclosed
WO-2007006814-A1 UREA GLUCOKINASE ACTIVATORS NOVO NORDISK A/S (DK) 2007-01-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090105482-A1 Urea Glucokinase Activators GCK, GCKR, HK2 LIPC 475/4885LIPG 687/4885MEN1 3615/4885
US-20110077234-A1 Urea Glucokinase Activators GCK, GCKR, HK2 LIPC 475/4885LIPG 687/4885MEN1 3615/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.